PanTheryx inks license agreement with Dr. Reddy’s Labs to distribute infectious diarrhea intervention product

Thursday September 10, 2015 0 comments Tags: Boulder, PanTheryx, DiaResQ, Mark A. Braman, Dr. Reddy's Laborato, GV Prasad

 

BOULDER -- PanTheryx Inc., a global medical nutrition company based in Boulder, and India-based Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) announced a multi-country supply and licensing agreement.Pantheryx_logoUSE

The agreement gives Dr. Reddy’s an exclusive right to market and distribute PanTheryx’s nutritional intervention – DiaResQ – to treat infectious diarrhea in India, Nepal, Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica and select LATAM markets, PanTheryx said.

“The opportunity to work with Dr. Reddy’s to broadly introduce DiaResQ represents a significant milestone for our company,” said Mark A. Braman, PanTheryx president and CEO.

“Dr. Reddy’s is the recognized leader in the gastrointestinal market, and this agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products.”

“This innovative product will address a significant unmet need in the area of diarrhea,” said GV Prasad, Dr. Reddy’s co-chair and CEO.

Infectious diarrhea is a major world health challenge, with 1.7 billion cases globally each year in children under five years old and nearly 760,000 deaths.